Century Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Century Therapeutics, Inc. (IPSC) had Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $5.25 million as of 2026-01-27, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-12
- Century Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $859.00K.
- Century Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $5.26M.
- Century Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Century Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Century Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $19.60M, a 494.81% increase from fiscal 2021.
- Century Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $3.29M, a 66.15% decline from fiscal 2020.
- Century Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $9.73M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2026-01-27 | $5.25M 10-Q · filed 2026-08-12 | ||||
| 2022-12-31 | $859.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $6.12M derived: sum of 2 quarters · filed 2024-03-14 | $19.60M 10-K · filed 2024-03-14 | ||
| 2022-09-30 | $5.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $18.74M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $13.48M 10-Q · filed 2023-08-09 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 derived: sum of 3 quarters · filed 2023-03-16 | $3.29M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $3.29M 10-Q · filed 2022-11-10 | $3.51M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $3.29M 10-Q · filed 2022-08-11 | $3.51M derived: sum of 3 quarters · filed 2022-08-11 | $10.03M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $3.29M 10-Q · filed 2022-05-16 | $3.51M derived: sum of 2 quarters · filed 2022-05-16 | $10.03M derived: sum of 3 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $213.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $6.74M derived: sum of 2 quarters · filed 2022-03-17 | $9.73M 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $6.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $9.52M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $3.00M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |